Compulsory Licensing and Pharmaceutical Patents: A Critical Evaluation of Public Health Concerns Author:

Abstract

The intersection of pharmaceutical patent protection and public health policy remains one of the most contentious issues in global intellectual property governance. While patent systems are intended to incentivize innovation by granting exclusive rights to inventors, their application in the pharmaceutical sector often raises concerns regarding drug affordability, accessibility, and equitable distribution—particularly in low- and middle-income countries. Compulsory licensing has emerged as a critical legal mechanism that allows governments to authorize the use of patented inventions without the consent of the patent holder under specific conditions, primarily to address public health emergencies and ensure access to essential medicines.

This study critically evaluates the legal, economic, and ethical dimensions of compulsory licensing within the framework of the TRIPS Agreement and the Doha Declaration on the TRIPS Agreement and Public Health. It examines landmark cases and national implementations of compulsory licensing, assessing their effectiveness in balancing innovation incentives with public health priorities. The research also explores tensions between developed and developing nations, pharmaceutical companies, and global health organizations regarding technology transfer, research and development costs, and market exclusivity.

Through doctrinal and comparative analysis, the paper argues that while compulsory licensing is a legitimate and necessary safeguard, procedural complexities and political pressures often limit its practical application. The study advocates for clearer international guidelines, enhanced transparency in licensing negotiations, and strengthened global cooperation to ensure that patent law supports both pharmaceutical innovation and the fundamental right to health.